Literature DB >> 366719

Auditory changes associated with moderate blood salicylate levels.

L Jardini, R Findlay, E Burgi, K Hinderer, A Agarwal.   

Abstract

Thirty patients with rheumatoid arthritis were randomly assigned to two groups: aspirin and placebo. Aspirin group subjects received five grain ASA capsules and placebo group subjects received lactose placebo for seven days. Blood salicylate level (BSL) and audiological evaluations were performed on Days 0, 3 and 7. BSLs never exceeded 21 mg/100 ml. BSLs during the seven days varied only slightly among aspirin group subjects but dropped consistently in the placebo group. Intra-subject comparison of scores on low versus high BSL days indicated significant differences between mean speech reception thresholds (SRT) scores and pure-tone air-conduction thresholds at all test frequencies for both groups, except at 2000 Hz for the aspirin group. Inter-group differences occurred on SRT and high-frequency pure-tone thresholds. The results indicate that moderate BSLs adversely affect hearing ability. These adverse effects appear to be temporary.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 366719     DOI: 10.1093/rheumatology/17.4.233

Source DB:  PubMed          Journal:  Rheumatol Rehabil        ISSN: 0300-3396


  4 in total

1.  Effect of salicylate on KCNQ4 of the guinea pig outer hair cell.

Authors:  T Wu; P Lv; H J Kim; E N Yamoah; A L Nuttall
Journal:  J Neurophysiol       Date:  2010-02-10       Impact factor: 2.714

Review 2.  Ubiquitous aspirin: a systematic review of its impact on sensorineural hearing loss.

Authors:  Meghann Elizabeth Kyle; James C Wang; Jennifer J Shin
Journal:  Otolaryngol Head Neck Surg       Date:  2014-10-30       Impact factor: 3.497

Review 3.  Ototoxicity associated with salicylates. A brief review.

Authors:  J A Brien
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

4.  Tinnitus as a measure of salicylate toxicity in the overdose setting.

Authors:  Scott R Samlan; Matthew T Jordan; Shu B Chan; Michael S Wahl; Rachel L Rubin
Journal:  West J Emerg Med       Date:  2008-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.